Skip to content

Study · Animal study (in vivo) · rat · 2024

12 results

SGLT-2 Inhibitors' and GLP-1 Receptor Agonists' Influence on Neuronal and Glial Damage in Experimental Stroke.

Murasheva A, Fuks O, Timkina N, Mikhailova A, Vlasov T, Samochernykh K, Karonova T

Biomedicines10 Dec 2024Cited by 5 (Europe PMC)

PMID39767704 (opens in a new tab)PMCIDPMC11673681 (opens in a new tab)DOI10.3390/biomedicines12122797 (opens in a new tab)PepBankPUB-39767704
Download PDFPubMedAsk about this study
Jump to 12 results

Summary

Background: SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) have demonstrated nephro- and cardioprotective effects, but their neuroprotective properties, especially concerning stroke severity, and mechanisms are not unambiguous. We aimed to study the influence of SGLT-2i with different selectivity and GLP-1RA on brain damage volume and neurological status in non-diabetic and diabetic rats and to investigate the underlying mechanisms. Methods: Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug. Control animals were administered 0.9% NaCl for 7 days before stroke. At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume. We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups. After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement. Results: In non-diabetic rats, all the drugs showed an infarct-limiting effect; SGLT-2i and dulaglutide were more effective than metformin. DULA improved neurological status compared with MET and SGLT-2i treatment. All the drugs decreased neurofilament light chains (NLCs) level and neuronal damage markers, but none of them decreased the glial damage marker S100BB. In DM, similarly, all the drugs had infarct-limiting effects. Neurological deficit was most pronounced in the untreated diabetic rats and was reduced by all study drugs. All the drugs reduced NLC level; dulaglutide and empagliflozin, but not canagliflozin, also decreased S100BB. None of the drugs affected neuron-specific enolase. Conclusions: SGLT-2i and GLP-1RA are neuroprotective in experimental stroke. GLP-1RA might be more effective than SGLT-2i as in non-diabetic conditions it influences both brain damage volume and neurological status. All study drugs decrease neuronal damage, while GLP-1RA and highly selective SGLT-2i EMPA, but not low-selective CANA, also have an impact on neuroglia in diabetic conditions.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic rats with stroke, dulaglutide limited infarct size versus control.

    In plain wordsIn non-diabetic rats with stroke, dulaglutide limited brain injury size compared with control.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInfarct volume in non-diabetic rats
    Study

    ratn: not reported in source

    Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In non-diabetic rats, all the drugs showed an infarct-limiting effect; SGLT-2i and dulaglutide were more effective than metformin.
    2 context sentences
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic rats with stroke, dulaglutide limited infarct size more than metformin.

    In plain wordsIn non-diabetic rats with stroke, dulaglutide limited brain injury size more than metformin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInfarct volume versus metformin in non-diabetic rats
    Study

    ratn: not reported in source

    Wistar rats with experimental stroke
    Comparator
    Metformin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In non-diabetic rats, all the drugs showed an infarct-limiting effect; SGLT-2i and dulaglutide were more effective than metformin.
    2 context sentences
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic rats with stroke, dulaglutide improved neurological status compared with metformin.

    In plain wordsIn non-diabetic rats with stroke, dulaglutide improved neurological status compared with metformin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseNeurological status versus metformin
    Study

    ratn: not reported in source

    Wistar rats with experimental stroke
    Comparator
    Metformin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    DULA improved neurological status compared with MET and SGLT-2i treatment.
    2 context sentences
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic rats with stroke, dulaglutide improved neurological status compared with SGLT-2 inhibitor treatment.

    In plain wordsIn non-diabetic rats with stroke, dulaglutide improved neurological status compared with SGLT-2 inhibitor treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseNeurological status versus SGLT-2 inhibitors
    Study

    ratn: not reported in source

    Wistar rats with experimental stroke
    Comparator
    SGLT-2 inhibitor treatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    DULA improved neurological status compared with MET and SGLT-2i treatment.
    2 context sentences
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic rats with stroke, dulaglutide decreased neurofilament light chains versus control, as did all tested drugs.

    In plain wordsIn non-diabetic rats with stroke, dulaglutide lowered a nerve injury marker compared with control, as did all tested drugs.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseNeurofilament light chains in non-diabetic rats
    Study

    ratn: not reported in source

    Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All the drugs decreased neurofilament light chains (NLCs) level and neuronal damage markers, but none of them decreased the glial damage marker S100BB.
    2 context sentences
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic rats with stroke, dulaglutide decreased neuronal damage markers versus control, as did all tested drugs.

    In plain wordsIn non-diabetic rats with stroke, dulaglutide lowered nerve injury markers compared with control, as did all tested drugs.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseNeuronal damage markers in non-diabetic rats
    Study

    ratn: not reported in source

    Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All the drugs decreased neurofilament light chains (NLCs) level and neuronal damage markers, but none of them decreased the glial damage marker S100BB.
    2 context sentences
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic rats with stroke, dulaglutide did not decrease S100BB versus control, as with all tested drugs.

    In plain wordsIn non-diabetic rats with stroke, dulaglutide did not lower S100BB compared with control, as with all tested drugs.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeS100BB in non-diabetic rats
    Study

    ratn: not reported in source

    Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All the drugs decreased neurofilament light chains (NLCs) level and neuronal damage markers, but none of them decreased the glial damage marker S100BB.
    2 context sentences
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with stroke, dulaglutide limited infarct size versus control, as did all tested drugs.

    In plain wordsIn diabetic rats with stroke, dulaglutide limited brain injury size compared with control, as did all tested drugs.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInfarct volume in diabetic rats
    Study

    ratn: not reported in source

    Diabetic Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In DM, similarly, all the drugs had infarct-limiting effects.
    4 context sentences
    Summary · context
    We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups.
    Summary · context
    After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement.
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with stroke, dulaglutide reduced neurological deficit compared with untreated diabetic rats.

    In plain wordsIn diabetic rats with stroke, dulaglutide reduced neurological problems compared with untreated diabetic rats.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseNeurological deficit in diabetic rats
    Study

    ratn: not reported in source

    Diabetic Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Neurological deficit was most pronounced in the untreated diabetic rats and was reduced by all study drugs.
    4 context sentences
    Summary · context
    We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups.
    Summary · context
    After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement.
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with stroke, dulaglutide reduced neurofilament light chains versus control, as did all tested drugs.

    In plain wordsIn diabetic rats with stroke, dulaglutide lowered a nerve injury marker compared with control, as did all tested drugs.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseNeurofilament light chains in diabetic rats
    Study

    ratn: not reported in source

    Diabetic Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All the drugs reduced NLC level; dulaglutide and empagliflozin, but not canagliflozin, also decreased S100BB.
    4 context sentences
    Summary · context
    We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups.
    Summary · context
    After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement.
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with stroke, dulaglutide decreased S100BB versus control.

    In plain wordsIn diabetic rats with stroke, dulaglutide lowered S100BB compared with control.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseS100BB in diabetic rats
    Study

    ratn: not reported in source

    Diabetic Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All the drugs reduced NLC level; dulaglutide and empagliflozin, but not canagliflozin, also decreased S100BB.
    4 context sentences
    Summary · context
    We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups.
    Summary · context
    After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement.
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with stroke, dulaglutide did not affect neuron-specific enolase versus control, as with all tested drugs.

    In plain wordsIn diabetic rats with stroke, dulaglutide did not change neuron-specific enolase compared with control, as with all tested drugs.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeNeuron-specific enolase in diabetic rats
    Study

    ratn: not reported in source

    Diabetic Wistar rats with experimental stroke
    Comparator
    Untreated control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    None of the drugs affected neuron-specific enolase.
    4 context sentences
    Summary · context
    We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups.
    Summary · context
    After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement.
    Summary · context
    Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
    Summary · context
    At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.